Victor Roberts, MD
Endocrinology, Diabetes & Metabolism · Lake Mary, FLNPI 1891725206
Payments from drug & device makers
Across 245 payments — averaging $52.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$5K
- Senseonics, Incorporated$4K
- Abbott$695
- Medtronic$576
- Xeris Pharmaceuticals, Inc.$439
- Sanofi-aventis U.S. LLC$321
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$8,95069%
- Food & beverage$3,97731%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 16 | $5,450 |
| Senseonics, Incorporated | 2 | $3,517 |
| Abbott | 36 | $695 |
| Medtronic(2 entities) | 51 | $576 |
| Xeris Pharmaceuticals, Inc. | 23 | $439 |
| Sanofi-aventis U.S. LLC | 15 | $321 |
| AbbVie | 14 | $248 |
| Amgen(2 entities) | 12 | $231 |
| Novo Nordisk | 10 | $181 |
| Dexcom, Inc. | 7 | $145 |
| Johnson & Johnson(2 entities) | 4 | $126 |
| Insulet Corporation | 6 | $112 |
| IBSA Pharma Inc. | 5 | $105 |
| Amneal Pharmaceuticals LLC | 6 | $103 |
| AstraZeneca(2 entities) | 4 | $83 |
| Lilly USA, LLC | 4 | $79 |
| Merck | 4 | $65 |
| Boehringer Ingelheim | 3 | $63 |
| Valeritas, Inc. | 4 | $62 |
| Acella Pharmaceuticals, LLC | 3 | $45 |
| Zealand Pharma US, Inc. | 2 | $33 |
| Antares Pharma, Inc. | 2 | $33 |
| Vistapharm, Inc. | 2 | $31 |
| Sequel Med Tech, LLC | 1 | $29 |
| Cequr Corporation | 1 | $24 |
| Corcept Therapeutics | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| Lifescan, Inc. | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$3,900
- Eversense$3,500
- t:slim X2 insulin pump$1,550
How this compares
$12,933 in reported general payments places this provider in the 70th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 385 | $551,060 |
| JardianceEmpagliflozin | 318 | $421,181 |
| OzempicSemaglutide | 235 | $405,505 |
| TrulicityDulaglutide | 158 | $261,308 |
| Tresiba Flextouch U-100Insulin Degludec | 153 | $121,300 |
| FarxigaDapagliflozin Propanediol | 100 | $116,999 |
| Humalog Kwikpen U-200Insulin Lispro | 36 | $113,740 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 86 | $112,457 |
| TradjentaLinagliptin | 90 | $108,633 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 72 | $105,677 |
| NovologInsulin Aspart | 178 | $97,077 |
| Humulin R U-500Insulin Regular, Human | 32 | $79,204 |
| JanuviaSitagliptin Phosphate | 54 | $66,319 |
| SynthroidLevothyroxine Sodium | 561 | $60,935 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 33 | $60,513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $79 | $854,669624 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Synjardy Xr | $63 | $572,694437 claims |
| Novo NordiskOzempic, Novolog, Rybelsus, Fiasp | $181 | $554,202445 claims |
| AstraZenecaFarxiga | $83 | $116,999100 claims |
| MerckJanuvia, Janumet | $65 | $98,32180 claims |
| AbbVieSynthroid | $248 | $60,935561 claims |
| AmgenProlia | $231 | $59,64134 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $321 | $30,60717 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $103 | $12,3931,221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Lake Mary
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
- Rodolfo GalindoMiami$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.